Fisher Alan 4

What Happened Alan Fisher, a director of Neuphoria Therapeutics, was granted 17,073 restricted stock units (RSUs) on 2026-01-20. The grant is reported as an award/acquisition (derivative) at $0.00 per unit — RSUs are a contingent right to receive one share each if vesting conditions are met. This is a compensation award rather than a purchase or sale.

Key Details

• Transaction date: 2026-01-20; Form 4 filed 2026-01-21 (timely; within required reporting window).
• Instrument and amount: 17,073 RSUs granted; reported price $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Each RSU converts into one common share upon vesting.
  • F2: Grant made under the Company’s Board of Directors annual remuneration policy.
  • F3: Vesting conditioned on continuous service through the earlier of (a) the day prior to the next annual shareholder meeting (expected by Dec 15, 2026) or (b) the effective date of a Change in Control.
• Filing timeliness: Appears timely (filed the day after the grant).

Context RSU awards are a common form of executive/director compensation and do not involve immediate cash changing hands or indicate an insider purchase/sale. Vesting conditions mean these units convert to shares only if Fisher remains in service (or upon a change in control, per the footnote). These grants are typically routine annual compensation and should be interpreted as such unless followed by further transactions (vesting, sales, or exercises).